Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia.
暂无分享,去创建一个
Wei Zhang | Yi Liu | Wei Zhang | Xiaobing Wang | Haimei Tian | Yi Liu | Brent Flickinger | Mark W Empie | Sam Z Sun | Hai-mei Tian | B. Flickinger | M. Empie | Xiaobing Wang | Sam Z. Sun
[1] C. Saussine,et al. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice , 2006, BJU international.
[2] I. Romics,et al. A novel approach to the treatment of benign prostatic hyperplasia , 2006, BJU international.
[3] T. Deguchi,et al. Comparison of two α1‐adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study , 2006, BJU international.
[4] T. Kitamura,et al. Clinical efficacy of an α1A/D‐adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia , 2006 .
[5] P. van’t Veer,et al. The relative bioavailability of enterolignans in humans is enhanced by milling and crushing of flaxseed. , 2005, The Journal of nutrition.
[6] H. Origasa,et al. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial , 2005, BJU international.
[7] A. Zlotta,et al. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. , 2005, European urology.
[8] Jørgen Nordling,et al. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia , 2005, BJU international.
[9] S. Hong,et al. Doxazosin for benign prostatic hyperplasia: An open‐label, baseline‐controlled study in Korean general practice , 2005, International journal of urology : official journal of the Japanese Urological Association.
[10] C. Roehrborn,et al. Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia , 2004 .
[11] D. Tindall,et al. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. , 2004, The Journal of urology.
[12] R. Sakakibara,et al. Single‐blind, randomized controlled study of the clinical and urodynamic effects of an α‐blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia , 2004, International journal of urology : official journal of the Japanese Urological Association.
[13] P. Boyle,et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. , 2004, European urology.
[14] N. Kyprianou,et al. Apoptotic impact of α1‐blockers on prostate cancer growth: A myth or an inviting reality? , 2004, The Prostate.
[15] R. Kirby,et al. Doxazosin controlled release vs tamsulosin in the management of benign prostatic hyperplasia: an efficacy analysis , 2004, International journal of clinical practice.
[16] C. Roehrborn,et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.
[17] A. Erol,et al. Short‐term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms , 2003, International journal of urology : official journal of the Japanese Urological Association.
[18] Y. Ogawa,et al. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia , 2003, International journal of urology : official journal of the Japanese Urological Association.
[19] I. Ikemoto,et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: A comparative, randomized, two‐drug crossover study , 2003, International journal of urology : official journal of the Japanese Urological Association.
[20] P. Åman,et al. High-performance liquid chromatographic analysis of secoisolariciresinol diglucoside and hydroxycinnamic acid glucosides in flaxseed by alkaline extraction. , 2003, Journal of chromatography. A.
[21] J. Eden,et al. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial , 2003, BJU international.
[22] R. Kirby. A randomized, double‐blind crossover study of tamsulosin and controlled‐release doxazosin in patients with benign prostatic hyperplasia , 2003, BJU international.
[23] H. Adlercreutz. Phyto-oestrogens and cancer. , 2002, The Lancet. Oncology.
[24] P. Boyle,et al. [Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study]. , 2002, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[25] W. Demark-Wahnefried,et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. , 2001, Urology.
[26] S. Kaplan,et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. , 2001, Urology.
[27] R. Kirby,et al. A combined analysis of double‐blind trials of the efficacy and tolerability of doxazosin‐gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia , 2001, BJU international.
[28] P. Narayan,et al. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH , 2000, Advances in therapy.
[29] J. Sökeland. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome , 2000, BJU international.
[30] M. Guil,et al. The clinical uroselectivity of alfuzosin is not significantly affected by the age of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia , 2000, BJU international.
[31] T. Tsujii. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: A short‐term open, randomized multicenter study , 2000, International journal of urology : official journal of the Japanese Urological Association.
[32] T. Senge,et al. Treatment of symptomatic benign prostatic hyperplasia with β‐sitosterol: an 18‐month follow‐up , 2000, BJU international.
[33] A. Partin,et al. Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. , 2000, The Journal of urology.
[34] S. Kamidono,et al. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients , 2000, BJU international.
[35] H. Mori,et al. Prediction of alpha-blocker response in men with benign prostatic hyperplasia by magnetic resonance imaging. , 1999, Urology.
[36] R. Guthrie,et al. A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT). , 1999, Clinical therapeutics.
[37] C. Chatelain,et al. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. , 1999, Urology.
[38] J. Trachtenberg,et al. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group. , 1999, Urology.
[39] P. Nesbitt,et al. Human metabolism of mammalian lignan precursors in raw and processed flaxseed. , 1999, The American journal of clinical nutrition.
[40] P. Boyle,et al. Double‐blind, placebo‐controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH , 1998, The Prostate.
[41] H. Lepor. Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial , 1998 .
[42] G. Chodak,et al. Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. , 1998, Urology.
[43] H. Lepor. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. , 1998, Urology.
[44] M. Marberger. Long-Term Effects of Finasteride in Patients with Benign Prostatic Hyperplasia: A Double-Blind, Placebo-Controlled, Multicenter Study , 1998 .
[45] J. Nickel. Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group. , 1998, British journal of urology.
[46] W. Witjes,et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. , 1997, British journal of urology.
[47] E. Lee,et al. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. , 1997, British journal of urology.
[48] K. Kawabe,et al. Transition zone ratio and prostate-specific antigen density as predictors of the response of benign prostatic hypertrophy to alpha blocker and anti-androgen therapy. , 1997, British journal of urology.
[49] E. Ghisalberti. Cardiovascular activity of naturally occurring lignans. , 1997, Phytomedicine : international journal of phytotherapy and phytopharmacology.
[50] K. Griffiths,et al. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. , 1995, The Journal of endocrinology.
[51] K. Griffiths,et al. Determination of lignans and isoflavonoids in human female plasma following dietary supplementation. , 1994, The Journal of endocrinology.
[52] C. Bosman,et al. Combination Therapy with Rofecoxib and Finasteride in the Treatment of Men with Lower Urinary Tract Symptoms (LUTS) and Benign Prostatic Hyperplasia (BPH) , 2005 .
[53] M. Safarinejad. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. , 2005, Journal of herbal pharmacotherapy.
[54] H. Preuss,et al. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH) , 2004, International Urology and Nephrology.
[55] H. Adlercreutz,et al. Phytoestrogens, cancer and coronary heart disease , 2004, BioFactors.
[56] L. Bloedon,et al. Flaxseed and cardiovascular risk. , 2004, Nutrition reviews.
[57] P. Wiesenfeld,et al. Effect of flaxseed consumption on male and female reproductive function and fetal development. , 2003 .
[58] P. Boyle,et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. , 2003, Urology.
[59] N. Kyprianou,et al. Induction of prostate apoptosis by α1-adrenoceptor antagonists: mechanistic significance of the quinazoline component , 2002, Prostate Cancer and Prostatic Diseases.
[60] P. V. Van Cangh,et al. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. , 2002, European urology.